glp 1 alzheimer's research Glucagon like peptide-1 (GLP-1) likes disease GLP-1 and Alzheimer's Disease: Research
Description
JPML has created a new multidistrict litigation for lawsuits alleging that GLP-1 receptor agonist drugs cause NAION, a serious vision injury.
Similar studies are ongoing in patients with metabolic liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), based on the known ability of GLP-1 to reduce fat levels in the liver
Our clinicians screen for this during assessment
GLP-1 Receptor Agonists and the Eye: Evidence, Mechanisms, and Clinical Guidance A new multidisciplinary expert consensus published in Diabetes, Obesity & Metabolism (2025) brings clarity to a question often raised in clinical practice: Do GLP-1 receptor agonists increase the risk of ocular complications such as diabetic retinopathy or optic neuropathy
doi:10.1001/jamanetworkopen.2024.57349
made in position 34 to ensure the attachment of only one fatty di-acid
